Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Cut to $50.00 by Analysts at TD Cowen

Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its target price reduced by TD Cowen from $65.00 to $50.00 in a research note issued to investors on Wednesday, Benzinga reports. TD Cowen currently has an outperform rating on the stock. A number of other brokerages also recently issued reports on ARQT. 500.com reaffirmed a reiterates rating […]

Related Keywords

Switzerland ,Swiss ,Arcutis Biotherapeutics ,Morgan Stanley ,Jpmorgan Chase Co ,Metlife Investment Management ,Dimensional Fund Advisors ,Arcutis Biotherapeutics Company Profile ,Needham Company ,Arcutis Biotherapeutics Inc ,Nasdaq ,Vanguard Group Inc ,Swiss National Bank ,Free Report ,Get Free Report ,National Bank ,Life Investment Management ,Fund Advisors ,Vanguard Group ,